Ivonescimab, an experimental lung cancer drug developed by Akeso and Summit Therapeutics, improved overall survival by 34% in a Phase 3 trial conducted in China, extending median survival by four months compared to standard immunotherapy plus chemotherapy. The drug targets PD-1 and VEGF proteins, combining mechanisms similar to Merck's Keytruda and Roche's Avastin. While promising for Chinese patients with squamous non-small-cell lung cancer, experts caution that results may vary in global populations and further studies are ongoing. Summit plans to release additional trial data later this year and next year to assess broader efficacy and safety.
Immunocore announced updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma patients, showing a 6-month overall survival rate of 87% and a disease control rate of 52%. The 160 mcg dose demonstrated better clinical outcomes and...
Apple's stock surged 15% in May, driven by optimism around its future in AI, particularly the potential of 'agentic smartphones.' Bank of America raised Apple's price target to $380, highlighting this AI opportunity as a key growth driver. Meanwhile,...
Victoria Hanrahan, a senior executive at Nokia, acquired a total of 44,682 Nokia shares on May 26 and May 28, 2026. The shares were purchased on the New York Stock Exchange at average prices of $16.02 and $15.60 respectively, with a combined average ...
Victoria Hanrahan, a senior manager at Nokia Corporation, purchased a total of 44,682 shares on May 26 and May 28, 2026. The shares were acquired on the New York Stock Exchange at an average price of $15.81 per share. This transaction signals confide...
Eli Lilly announced that the Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) significantly improved event-free survival by reducing the risk of recurrence or death by 83% compared to placebo in early-stage RET fusion-positive non-small cell lun...
